Actinium Pharmaceuticals, Inc.
NYSE · Healthcare · Pharmaceutical Preparations · New York, NY
ATNM chart
What traders are saying about $ATNM
Latest postsActinium Pharmaceuticals, Inc. news
- Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Yahoo Finance ·
- Actinium Pharmaceuticals, Inc. (Delaware) Estimates – AMEX:ATNM
TradingView ·
- Actinium Pharmaceuticals, Inc. (ATNM) stock price, news, quote and history
Yahoo Finance Australia ·
- Actinium Pharmaceuticals initiates study of HER3 targeted radiotherapy in prostate cancer
Traders Union ·
- Actinium Pharmaceuticals, Inc. Highlights First-In-Human Phase 1 Study of Atnm-400 A Her3-Targeted Non-Psma Radiotherapy in Prostate Cancer At Esmo 2026
marketscreener.com ·
- Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026
Yahoo Finance ·
- Analysts’ Top NA Picks: Rapport Therapeutics, Inc. (RAPP), SpaceX (SPCX)
The Globe and Mail ·
- Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer
Yahoo Finance ·
- Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models
Yahoo Finance ·
- Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026
Yahoo Finance ·
- Actinium Pharmaceuticals Announces Inducement Grants to New Employees
Yahoo Finance ·
- ATNM: Introduction to Radiopharmaceuticals
Yahoo Finance ·
Actinium Pharmaceuticals, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $90,000 | – | $81,000 | $1.0M |
| Net income | -$33.9M | -$38.2M | -$48.8M | -$33.0M |
| Diluted EPS | $-1.09 | $-1.27 | $-1.83 | $-1.37 |
| Total assets (year end) | $51.8M | $76.9M | $81.4M | $114.2M |
| Cash and equivalents (year end) | $48.0M | $72.9M | $76.7M | $108.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Actinium Pharmaceuticals, Inc.
- Ticker
- ATNM (NYSE)
- Industry
- Pharmaceutical Preparations
- Headquarters
- New York, NY
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1388320
- Former names
- Cactus Ventures, Inc.
Frequently asked questions
What exchange is Actinium Pharmaceuticals, Inc. listed on?
Actinium Pharmaceuticals, Inc. trades on the NYSE under the ticker symbol ATNM.
What industry is Actinium Pharmaceuticals, Inc. in?
Actinium Pharmaceuticals, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Actinium Pharmaceuticals, Inc. headquartered?
Actinium Pharmaceuticals, Inc.'s business address on file with the SEC is in New York, NY.
When does Actinium Pharmaceuticals, Inc.'s fiscal year end?
Actinium Pharmaceuticals, Inc.'s fiscal year ends on December 31.
How much revenue did Actinium Pharmaceuticals, Inc. report?
Actinium Pharmaceuticals, Inc. reported $90,000 in revenue for calendar year 2025, according to its SEC filings.